MacroGenics' Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

Maryland-based MacroGenics’ metastatic HER2-positive breast cancer treatment margetuximab continues to show promise following a second pre-planned interim overall survival analysis of its Phase III SOPHIA trial.